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Introduction: In Europe a disease is recognized as rare if less than 1 in 2000 people suffer from   
the specific disease. In patients with familial homozygous hypercholesterolemia (HoFH) the 
accumulation of low-density lipoprotein cholesterol (LDL-C) leads to generalized   atherosclerosis 
due to an insufficient functioning of the LDL-C receptors. Patients die early sometimes even 
in the mid-30s, from   myocardial infarction or stroke. For the German population, insufficient 
epidemiological evidence exists.
Methods: A systematic literature search in EMBASE and Medline was performed in   conjunction 
with a targeted manual search for epidemiological HoFH studies. Additionally a nationwide 
survey was conducted in Germany in all identified apheresis- and lipid centers. The purpose 
of the survey was the validation of the systematic literature search results based on empirical 
(practice) data.
Results: In total 961 publications were found, 874 were excluded based on pre-defined exclu-
sion criteria leaving only 87 for further review. After review of the identified abstracts (n = 87) 
23 publications were identified as epidemiological studies. Only one publication was found 
which reported a prevalence of 1:1,000,000. The qualitative survey among 187 physicians in 
Germany also revealed a low prevalence: 95 HoFH patients were identified in 35 centers.
Conclusion: The estimated frequency of homozygous familial hypercholesterolemia patients 
in Germany is around 95 (1:860,000) and the disease should be recognized as rare according 
to the definition of the European Medical Agency.
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Introduction
The European Medicine Agency (EMA) defines a disease as orphan if the disease 
is   life-threatening or a chronically debilitating condition affecting no more than 
5 in 10,000 people in the European Union (EU) at the time of submission of the 
designated drug application to the EMA. Additionally there must also be either no 
  satisfactory method of diagnosis, prevention or treatment of the condition concerned 
being   authorized, or, if such a method does exists, the treatment must be of significant 
benefit to those affected by the condition.1
Homozygous familiar hypercholesterolemia (HoFH) is a rare, inherited, genetic 
disorder affecting the low density lipoprotein cholesterol (LDL-C) metabolism, which 
results in greatly elevated blood cholesterol levels. It is most commonly caused by 
mutations in both alleles of the LDL receptor (LDLR) gene, but may potentially also 
be caused by mutations in the ApoB gene or proprotein convertase subtilisin/kexin 
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type 9 gene. Mutations of the LDLR gene account for 85% 
to 90% of cases.2 Patients with HoFH may have two identi-
cal mutations (true homozygote) or two different mutations 
(compound heterozygote).3 HoFH is related to the more com-
mon disorder heterozygous familial hypercholesterolemia 
(HeFH). In HeFH, only one copy of the affected gene carries 
a mutation, preserving a variable level of normal LDL-C 
metabolism, which typically leads to less elevated LDL-C 
levels and a less severe disease course relative to HoFH.4
HoFH is an autosomal codominant disease,5 such that 
both parents of a homozygote patient must have at least one 
copy of the relevant mutation and are thus HeFH or HoFH 
patients themselves. The mutations which cause HoFH lead 
to failure of the removal of ApoB-containing lipoprotein par-
ticles and LDL-C from the blood by the LDLR5 resulting in an 
accumulation of LDL-C to levels far exceeding those in the 
general population; total cholesterol levels can range from 650 
to 1000 mg/dL,3 with LDL-C levels . 500 mg/dL in untreated 
patients with HoFH. As HoFH is a disease affecting patients’ 
daily life it can be assumed that all patients receive treatment.
Exposure to chronically high cholesterol levels leave 
HoFH patients highly vulnerable to the development of 
atherosclerosis and cardiovascular disease (CVD).6 Rates 
of CVD are not only very high, but CVD can develop at a 
very early age in HoFH patients. For example, evidence of 
atherosclerosis, coronary heart disease and aortic stenosis 
may become detectable already during childhood.7,8 HoFH 
patients have a greatly reduced life expectancy, with a large 
proportion of patients suffering fatal coronary insufficiency or 
myocardial infarction before the age of 30 years.7,8
The excessively high levels of LDL-C associated 
with HoFH lead to visible signs of cholesterol build-up 
  (xanthoma) in the skin and joints as well as around tendons, 
especially at the Achilles tendon and tendons of the fingers. 
  Cholesterol depositions in the cornea may be present   leading 
to a characteristic white-ringed appearance of the iris (arcus 
cornealis).4
HoFH is an extremely rare orphan disease, the exact 
  prevalence of which is unknown. However it is thought 
to affect one person per million,3 which would lead to an 
  estimated 82 patients in Germany, based on current esti-
mates of the German population in 2012. However, the 
  epidemiological data for Germany is insufficient and only 
little   epidemiological evidence is known.
Methods
A systematic literature search was performed utilizing the 
MEDLINE and Embase databases. Before the search the 
following research frame using the PICOS (Patient, Interven-
tion, Comparison, Outcome, Setting) criteria was defined:
•	 Patient: familial homozygous hypercholesterolemia 
(HoFH).
•	 Intervention: epidemiological studies.
•	 Comparator: not applicable.
•	 Outcome: epidemiology (prevalence and/or incidence of 
HoFH).
•	 Setting: Germany.
The combined searches of MEDLINE and Embase yielded 
961 unique abstracts; additional articles were identified upon 
evaluation of the bibliographies of review articles.
In the first level of screening, each abstract was evalu-
ated independently by one investigator for inclusion in the 
study according to the inclusion and exclusion criteria. 
Any decision to exclude a study was reviewed by a second 
investigator. Any discrepancies in these decisions were 
reviewed and resolved by a third investigator. For abstracts 
that were deemed relevant during the first level of review, 
full articles were retrieved and reviewed.
Inclusion criteria for abstracts selected for retrieval were 
studies published in English and German language evaluating 
humans, published since 1980, reporting outcomes relevant 
to the epidemiology for HoFH. Studies including different 
groups, such as patients with heterozygous familial hyper-
cholesterolemia (HeFH), were allowed provided the data 
were reported separately for the HoFH population. Exclusion 
criteria included articles published prior to 1980 and studies 
without epidemiological outcomes. If studies only included 
HeFH patients they were excluded. In vitro studies; animal; 
fetal; molecular; genetic; and pharmacokinetics/pharmaco-
dynamics studies; narrative reviews published prior to May 
2009; expert opinions; case reports; meeting abstracts; and 
editorials were excluded from this review.
Information from the full text articles reporting clinical 
outcomes related to treatment of HoFH were extracted and 
abstracted by a single investigator, with a second senior 
investigator validating the extracted information indepen-
dently; any differences were resolved by discussion with a 
third investigator.
In order to get a complete and supplementary epidemiologi-
cal overview of HoFH patients in Germany, a survey was con-
ducted in Germany in all identified apheresis- and lipid centers. 
The purpose of the survey was the validation of the systematic 
literature search results based on empirical data. As a starting 
point all centers treating HoFH patients were identified before 
the survey start. As a second step all apheresis centers and lipid 
ambulances for which contact details could be identified were 
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contacted (one priority group (14 contacts), one apheresis center 
group (103 contacts), one lipid ambulance group (45 contacts), 
for a total 162 contacts). All contacts were contacted first by 
email, and followed up by phone if they did not respond to 
emails. This direct contact by telephone helped enlarge the 
contact database by 25 physicians to a total of 187.
Results
Of the 961 abstracts reviewed, 207 articles were selected 
for further review in full text, and 754 were excluded (see 
Figure 1). Of the 207 full text articles reviewed, 23 of the 
identified articles consisted of epidemiological information 
(overview of the 23 articles available on request).
The prevalence of HoFH is often cited as 1:1,000,000 in 
the general population; however, our review identified only 
one citation with this figure, another citation supporting 
and citing this prevalence was found by the related hand 
search.3,9 Six other publications10–15 identified in this review, 
describe higher estimates for HoFH prevalence. All were 
cross-sectional surveys of HoFH patients, in varying regions 
of the world, with estimates of HoFH prevalence ranging 
from 1:30,000 in a cross-sectional survey of a South African 
population,14 to 1:640,000 from a survey of 10,889 Dutch 
individuals.12 The estimates in this review suggest a higher 
general prevalence of HoFH than the 1:1,000,000; however, 
the role of founder effects and observational bias cannot 
necessarily be discounted.
Our qualitative survey with 187 physicians in Germany 
also demonstrated a low prevalence: 95 HoFH patients 
were identified. The reported HoFH patient numbers for the 
defined four German regions are visualized within Figure 2.
Discussion
Patients with this rare and severe disease have only limited 
treatment options available. Besides very limited effective 
therapies (lipid-lowering drugs such as statins, diet) LDL-
apheresis in conjunction with a maximum lipid-lowering 
drug therapy and diet is accepted in Germany as the standard 
of care for those patients. Based on this treatment paradigm 
the qualitative survey was developed around the German 
apheresis and lipid-ambulance centers in order to recruit and 
contact physicians to define a thorough epidemiological basis 
of HoFH in Germany. This approach has had the advantage of 
optimizing the likelihood of catching the majority of HoFH 
patients in Germany for the survey. As potential limitations 
the normal drawbacks of any qualitative approach apply, 
especially the potential reporting bias by physicians or the 
688 publications identified from MEDLINE
via PubMed 
654 publications identified from Embase 
961 unique publications identified after
removing duplicates  
207 full text articles retrieved for
detailed evaluation 
754 publications excluded after abstract
screening  
132 publications excluded after full text
screening  
77 total publications included for
abstraction  
• 23 epidemiology – one study
related to Germany  
2 publications included from manual
reference checks 
Figure  1  Literature  search  process  for  epidemiology  evidence  of  homozygous 
familial hypercholesterolemia (HoFH) in Germany.
Region:
Southern Germany (BY, BW): 26 patients
Eastern Germany (TH, SN, SA, BB, BE): 13 patients
Western Germany (SL, RP, HE, NRW): 42 patients
Northern Germany (NS, HB, HH, SH, MV): 14 patients
München
Baden-
Württemberg (BW)
Bayern (BY) Stuttgart
Saarland (SL)
Saar-
brücken
Mainz
Rheinland-
Pfalz (RP)
Wiesbaden
Hessen (HE)
Erfurt
Thüringen (TH)
Dresden
Sachsen
(SN)
Düsseldorf
Nordrhein-
Westfalen (NRW)
Magdeburg
Sachsenanhalt (SA)
Potsdarn
Berlin
(BE)
Brandenburg (BB)
Hannover
Niedersachsen(NS)
Bremen
(HB)
Schleswig-
Holstein (SH)
Kiel
Schwerin Mecklenburg-
Vorpommern MV)
Figure 2 German HoFH patients in the different regions according to the qualitative 
survey.
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possibility of patient duplicate counting due to the possible 
treatment of one patient in an apheresis center and a lipid-
ambulance around the same time.
Specifically for this research the following limitations 
apply: There might be double-counts among the 95 identified 
HoFH patients as no validation or formal check was being 
done. Hence this bias could have an effect in decreasing the 
actual number of patients. Additionally a few centers did 
not respond to the survey which may result in a potential 
increase in the estimated number of patients, if they did 
in-effect have patients with HoFH. Furthermore some phy-
sicians did not respond consistently to the survey as they 
responded as having HoFH patients in the screening phase 
of the project but did not provide patient data during the 
data collection phase.
Otherwise, to the best of our knowledge this is the 
first scientific attempt to define the epidemiological basis 
of homozygous familial hypercholesterolemia patients in 
Germany.
Conclusion
The estimated frequency of homozygous familial hypercho-
lesterolemia patients in Germany is around 95 (1:860,000) 
and the disease should hence be recognized as a rare one 
according to the definition of the European Medical Agency. 
Further research in order to identify the correct number of 
HoFH patients in Germany is warranted.
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